|
122 Companies |
|
195 Products |
|
195 Products |
|
116 Mechanisms of Action |
|
3 Trials |
|
2333 News |
|
| «12...1819202122232425262728...4647» |
- | BN82451 / Ipsen
Enrollment open: Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients (clinicaltrials.gov) - Oct 2, 2014
P2a, N=30, Recruiting, Sponsor: Ipsen
Not yet recruiting --> Recruiting
- pioglitazone / Generic mfg.
Enrollment closed, Trial primary completion date: Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors (clinicaltrials.gov) - Oct 2, 2014
P1, N=100, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2012 --> Sep 2014
- | Enrollment closed, Enrollment change, Trial primary completion date: Can Exercise Improve Cancer Associated Cognitive Dysfunction? (clinicaltrials.gov) - Sep 30, 2014
P2, N=31, Active, not recruiting, Sponsor: University of British Columbia
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2012 --> Sep 2014 Recruiting --> Active, not recruiting | N=60 --> 31 | Trial primary completion date: Jan 2013 --> Feb 2014
- | Daliresp (roflumilast) / AstraZeneca, Takeda, AbbVie
Trial completion, Combination therapy: Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults (clinicaltrials.gov) - Sep 30, 2014
P1, N=27, Completed, Sponsor: Takeda
Recruiting --> Active, not recruiting | N=60 --> 31 | Trial primary completion date: Jan 2013 --> Feb 2014 Active, not recruiting --> Completed
- Trial primary completion date: MACAP: Capacity Assessment in Persons With Alzheimer's Disease (clinicaltrials.gov) - Sep 29, 2014
P=N/A, N=400, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed Trial primary completion date: Dec 2013 --> Dec 2014
- Trial completion: Animal-assisted Interventions in Health Promotion for Elderly With Dementia (clinicaltrials.gov) - Sep 29, 2014
P=N/A, N=122, Completed, Sponsor: Norwegian University of Life Sciences
Trial primary completion date: Dec 2013 --> Dec 2014 Recruiting --> Completed
- Trial completion: Animal-assisted or Robot-assisted Interventions in Health Promotion for Elderly With Dementia (clinicaltrials.gov) - Sep 29, 2014
P=N/A, N=88, Completed, Sponsor: Norwegian University of Life Sciences
Recruiting --> Completed Recruiting --> Completed
- ||| PF-05236812 / J&J, Pfizer
Trial completion, Enrollment change: Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Sep 29, 2014
P1, N=52, Completed, Sponsor: Pfizer
Recruiting --> Completed Active, not recruiting --> Completed | N=104 --> 52
- ||||| semagacestat (LY450139) / Eli Lilly
Enrollment change: Effect of LY450139 on the Long Term Progression of Alzheimer's Disease (clinicaltrials.gov) - Sep 28, 2014
P3, N=1537, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed | N=104 --> 52 N=164 --> 1537
- citalopram / Generic mfg., venlafaxine / Generic mfg., donepezil / Generic mfg.
Trial primary completion date: DEP-CI: Combination Treatment Study for Memory Impairment and Depression (clinicaltrials.gov) - Sep 28, 2014
P4, N=80, Recruiting, Sponsor: New York State Psychiatric Institute
N=164 --> 1537 Trial primary completion date: Aug 2014 --> Mar 2015
- Clinical: An Exploratory Study to Compare the Differences in Nutritional Status Between Patients With Mild and Moderate Alzheimer's Disease (AD) and Cognitively Intact Healthy People in an Asian Population (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=225, Not yet recruiting, Sponsor: PTSH Holding Singapore Pte Ltd
- || New P2/3 trial: Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type (clinicaltrials.gov) - Sep 28, 2014
P2/3, N=198, Terminated, Sponsor: Boehringer Ingelheim
- | New P2 trial: Efficacy and Safety of Talsaclidine (Free Base) in Patients With Mild to Moderate Dementia of Alzheimer Type (clinicaltrials.gov) - Sep 28, 2014
P2, N=54, Terminated, Sponsor: Boehringer Ingelheim
- ||||| New P2 trial: Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type (clinicaltrials.gov) - Sep 28, 2014
P2, N=362, Completed, Sponsor: Boehringer Ingelheim
- PBF-999 / Palobiofarma
Enrollment open: Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers (clinicaltrials.gov) - Sep 28, 2014
P1, N=32, Recruiting, Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Trial primary completion date: Aug 2014 --> Mar 2015 Not yet recruiting --> Recruiting
- Enrollment open, Trial primary completion date: The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury (clinicaltrials.gov) - Sep 28, 2014
P3, N=15, Recruiting, Sponsor: Brock University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2014 --> Feb 2015
- minocycline / Generic mfg.
Trial completion, Enrollment change: Minocycline in Patients With Alzheimer's Disease (clinicaltrials.gov) - Sep 28, 2014
P2, N=13, Completed, Sponsor: Huntington Medical Research Institutes
Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2014 --> Feb 2015 Recruiting --> Completed | N=120 --> 13
- | Trial completion: Valproate in Dementia (VALID) (clinicaltrials.gov) - Sep 24, 2014
P3, N=313, Completed, Sponsor: Alzheimer's Disease Cooperative Study (ADCS)
Recruiting --> Completed | N=120 --> 13 Active, not recruiting --> Completed
- blarcamesine (Anavex 2-73) / Anavex
New P2 trial, New P2a trial, PK/PD data: Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease (clinicaltrials.gov) - Sep 22, 2014
P2a, N=32, Not yet recruiting, Sponsor: Anavex Life Sciences Corp.
- | encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
New P2 trial: Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine (clinicaltrials.gov) - Sep 22, 2014
P2, N=150, Not yet recruiting, Sponsor: FORUM Pharmaceuticals Inc
- | gantenerumab (RG1450) / Roche, MorphoSys
Trial completion: A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients (clinicaltrials.gov) - Sep 22, 2014
P1, N=28, Completed, Sponsor: Chugai Pharmaceutical
Active, not recruiting --> Completed Recruiting --> Completed
- |||| Trial completion: Evaluation of Reader Training Processes (clinicaltrials.gov) - Sep 19, 2014
P4, N=241, Completed, Sponsor: Avid Radiopharmaceuticals
Recruiting --> Completed Recruiting --> Completed
- | vanutide cridificar (PF-236806) / J&J, Perrigo Company, Pfizer
Trial termination: Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease (clinicaltrials.gov) - Sep 19, 2014
P2a, N=53, Terminated, Sponsor: Pfizer
Recruiting --> Completed Completed --> Terminated
- | Enrollment change: Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls. (clinicaltrials.gov) - Sep 19, 2014
P2, N=34, Completed, Sponsor: Avid Radiopharmaceuticals
Completed --> Terminated N=28 --> 34
- |||| Trial completion: The Feasibility of Florbetapir Quantitation in Europe (clinicaltrials.gov) - Sep 19, 2014
P4, N=96, Completed, Sponsor: Avid Radiopharmaceuticals
N=28 --> 34 Recruiting --> Completed
- ||||| osoresnontrine (BI 409306) / Boehringer Ingelheim
New P2 trial: Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo (clinicaltrials.gov) - Sep 16, 2014
P2, N=288, Not yet recruiting, Sponsor: Boehringer Ingelheim
- resveratrol (DB02709) / Alzheimer's Disease Cooperative Study
Biomarker, Trial completion, Trial primary completion date: Resveratrol for Alzheimer's Disease (clinicaltrials.gov) - Sep 16, 2014
P2, N=120, Completed, Sponsor: Alzheimer's Disease Cooperative Study (ADCS)
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Mar 2014
- Trial completion: HBA: Home-Based Assessment for Alzheimer Disease Prevention (clinicaltrials.gov) - Sep 16, 2014
P=N/A, N=640, Completed, Sponsor: Alzheimer's Disease Cooperative Study (ADCS)
Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Mar 2014 Active, not recruiting --> Completed
- sevoflurane / Generic mfg.
Trial primary completion date, Surgery: HIPELD: Hip Fracture Surgery in Elderly Patients (clinicaltrials.gov) - Sep 16, 2014
P2, N=256, Recruiting, Sponsor: Air Liquide Sant
Active, not recruiting --> Completed Trial primary completion date: May 2014 --> Dec 2014
- ||| KHK6640 / Kyowa Kirin
Enrollment open: A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Sep 16, 2014
P1, N=62, Recruiting, Sponsor: Kyowa Hakko Kirin Pharma, Inc.
Trial primary completion date: May 2014 --> Dec 2014 Not yet recruiting --> Recruiting
- | Enrollment closed, Trial primary completion date: Deep Transcranial Magnetic Stimulation for Treatment of Alzheimer's Disease (clinicaltrials.gov) - Sep 16, 2014
P2, N=45, Active, not recruiting, Sponsor: Brainsway
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Aug 2015
- ||| Aduhelm (aducanumab) / Eisai, Biogen
Trial completion, Trial primary completion date: Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease (clinicaltrials.gov) - Sep 16, 2014
P1, N=53, Completed, Sponsor: Biogen Idec
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Aug 2015 Active, not recruiting --> Completed | Trial primary completion date: Feb 2013 --> Aug 2013
- | OMS824 / Omeros
Enrollment change: Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease (clinicaltrials.gov) - Sep 12, 2014
P2, N=36, Recruiting, Sponsor: Omeros Corporation
Active, not recruiting --> Completed | Trial primary completion date: Feb 2013 --> Aug 2013 N=120 --> 36
- New P2 trial: NMDA-enhancing Agent for the Treatment of Mild Cognitive Impairment (clinicaltrials.gov) - Sep 12, 2014
P2, N=50, Recruiting, Sponsor: Chang Gung Memorial Hospital
- AADvac1 / Axon Neurosci
Enrollment open: FUNDAMANT: 18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease (clinicaltrials.gov) - Sep 12, 2014
P1, N=30, Recruiting, Sponsor: Axon Neuroscience SE
N=120 --> 36 Not yet recruiting --> Recruiting
- ||| Trial completion, Trial primary completion date: Longitudinal Study of Cognition With Niemann-Pick Disease, Type C (clinicaltrials.gov) - Sep 12, 2014
P=N/A, N=70, Completed, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Sep 2014
- Clinical: ACES: The Aerobic & Cognitive Exercise Study (clinicaltrials.gov) - Sep 11, 2014
P=N/A, N=90, Recruiting, Sponsor: Union College, New York
- Enrollment closed: Shanghai Mild Cognitive Impairment Cohort Study (clinicaltrials.gov) - Sep 11, 2014
P=N/A, N=400, Active, not recruiting, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Sep 2014 Recruiting --> Active, not recruiting
- ||||||| Trial completion, Enrollment change, Trial primary completion date: Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease (clinicaltrials.gov) - Sep 11, 2014
P3, N=365, Completed, Sponsor: GE Healthcare
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=225 --> 365 | Trial primary completion date: Apr 2014 --> Jan 2014
- Trial completion, Trial primary completion date: REVEAL III: Risk Evaluation and Education for Alzheimer's Disease (clinicaltrials.gov) - Sep 11, 2014
P=N/A, N=290, Completed, Sponsor: Brigham and Women's Hospital
Active, not recruiting --> Completed | N=225 --> 365 | Trial primary completion date: Apr 2014 --> Jan 2014 Active, not recruiting --> Completed | Trial primary completion date: Mar 2010 --> Oct 2009
- Enrollment open: A Pilot Study to Reduce Inappropriate Anticholinergic Prescribing in the Elderly (clinicaltrials.gov) - Sep 10, 2014
P=N/A, N=50, Recruiting, Sponsor: Daniela Moga
Active, not recruiting --> Completed | Trial primary completion date: Mar 2010 --> Oct 2009 Not yet recruiting --> Recruiting
- atabecestat (JNJ-54861911) / J&J
Trial primary completion date: A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease (clinicaltrials.gov) - Sep 10, 2014
P1, N=48, Recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2014 --> Dec 2014
- haloperidol / Generic mfg.
Trial primary completion date: HARPOON: Haloperidol Prophylaxis in Older Emergency Department Patients (clinicaltrials.gov) - Sep 9, 2014
P4, N=780, Recruiting, Sponsor: VU University Medical Center
Trial primary completion date: Aug 2014 --> Dec 2014 Trial primary completion date: May 2015 --> Nov 2015
- memantine ER / Generic mfg., galantamine extended release / Generic mfg.
New P2 trial: Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia (clinicaltrials.gov) - Sep 9, 2014
P2, N=10, Not yet recruiting, Sponsor: Sheppard Pratt Health System
- Aplenzin (bupropion hydrobromide ER) / Bausch Health
Trial completion: Action-HD: Apathy Cure Through Bupropion in Huntington's Disease (clinicaltrials.gov) - Sep 9, 2014
P2, N=40, Completed, Sponsor: Charite University, Berlin, Germany
Trial primary completion date: May 2015 --> Nov 2015 Active, not recruiting --> Completed
- sevoflurane / Generic mfg.
Trial completion: POCD in Elderly Patients Following Desflurane or Sevoflurane General Anesthesia (clinicaltrials.gov) - Sep 9, 2014
P=N/A, N=110, Completed, Sponsor: Loma Linda University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment open: Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants (clinicaltrials.gov) - Sep 8, 2014
P1, N=34, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| LMTX (hydromethylthionine) / TauRx
Trial initiation date: Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease (clinicaltrials.gov) - Sep 5, 2014
P3, N=700, Ongoing, Sponsor: TauRx Therapeutics Ltd
Not yet recruiting --> Recruiting Initiation date: Nov 2012 --> Apr 2013
- | BN82451 / Ipsen
New P2a trial: Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients (clinicaltrials.gov) - Sep 5, 2014
P2a, N=30, Not yet recruiting, Sponsor: Ipsen
- Clinical: IDEA_TANZANIA_CST1: IDEA Study Cognitive Stimulation Therapy (CST) Trial in Tanzania (clinicaltrials.gov) - Sep 4, 2014
P=N/A, N=16, Enrolling by invitation, Sponsor: William Keith Gray